Research Analysts Issue Forecasts for XENE FY2025 Earnings

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Stock analysts at Cantor Fitzgerald dropped their FY2025 earnings estimates for shares of Xenon Pharmaceuticals in a research note issued on Tuesday, May 13th. Cantor Fitzgerald analyst J. Schimmer now anticipates that the biopharmaceutical company will earn ($3.43) per share for the year, down from their prior forecast of ($3.20). The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.10) per share.

Other equities research analysts also recently issued reports about the stock. Deutsche Bank Aktiengesellschaft began coverage on shares of Xenon Pharmaceuticals in a research note on Tuesday, February 11th. They issued a “buy” rating and a $67.00 target price for the company. Wells Fargo & Company lowered their price objective on shares of Xenon Pharmaceuticals from $50.00 to $47.00 and set an “overweight” rating for the company in a research note on Tuesday. Royal Bank of Canada reduced their target price on shares of Xenon Pharmaceuticals from $58.00 to $55.00 and set an “outperform” rating for the company in a report on Tuesday. HC Wainwright reaffirmed a “buy” rating and issued a $53.00 price objective on shares of Xenon Pharmaceuticals in a report on Tuesday. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $55.00 price objective on shares of Xenon Pharmaceuticals in a report on Tuesday. One analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $54.82.

Xenon Pharmaceuticals Stock Performance

NASDAQ XENE opened at $29.57 on Thursday. The firm’s 50 day moving average price is $34.19 and its 200-day moving average price is $38.03. Xenon Pharmaceuticals has a 52-week low of $26.74 and a 52-week high of $46.00. The company has a market cap of $2.26 billion, a PE ratio of -10.49 and a beta of 1.21.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.83) EPS for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.07. The company had revenue of $7.50 million during the quarter, compared to the consensus estimate of $1.64 million. During the same quarter in the prior year, the company earned ($0.62) earnings per share.

Institutional Trading of Xenon Pharmaceuticals

Large investors have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd purchased a new stake in Xenon Pharmaceuticals during the 1st quarter valued at about $30,000. GF Fund Management CO. LTD. purchased a new stake in Xenon Pharmaceuticals during the 4th quarter valued at about $63,000. Quarry LP purchased a new stake in Xenon Pharmaceuticals during the 4th quarter valued at about $78,000. Blue Trust Inc. grew its stake in Xenon Pharmaceuticals by 140.3% during the 4th quarter. Blue Trust Inc. now owns 2,422 shares of the biopharmaceutical company’s stock valued at $95,000 after acquiring an additional 1,414 shares in the last quarter. Finally, Avior Wealth Management LLC purchased a new stake in shares of Xenon Pharmaceuticals in the 4th quarter valued at approximately $101,000. Hedge funds and other institutional investors own 95.45% of the company’s stock.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.